CAML

Dynam.AI Named a Cool Vendor in 2022 Gartner® Cool Vendors™ for Simulation in AI

Retrieved on: 
Monday, January 9, 2023
Physics, Algorithm, COOL, Research, Artificial intelligence, Publication, Risk, SAN, Foot-pound (energy), Internet of things, AI, CAML, Machine learning, Gartner, ROI, IOT, Context, Medical device, Software

SAN DIEGO, Jan. 9, 2023 /PRNewswire-PRWeb/ -- Dynam.AI, an artificial intelligence (AI) software development firm automating critical decision-making for the industrial sector, today announced that it has been named a Cool Vendor by Gartner. Gartner delivers actionable, objective insight to executives and their teams. Their expert guidance and tools enable faster, smarter decisions and stronger performance on an organization's most critical priorities. In a report titled, "Cool Vendors for Simulation in AI" by Anthony Mullen, et al, Gartner authors stated that "simulation technologies can help AI practitioners scale the volume and variety of AI models produced as well as reducing risk and technical debt."

Key Points: 
  • The leading analyst firm recognized Dynam.AI as a ' Cool Vendor' in the simulation AI space in a December 2022 report.
  • In a report titled, "Cool Vendors for Simulation in AI" by Anthony Mullen, et al, Gartner authors stated that "simulation technologies can help AI practitioners scale the volume and variety of AI models produced as well as reducing risk and technical debt."
  • The report's findings include:
    Many buyers and AI practitioners are unfamiliar with simulation technologies and their relationship with AI.
  • "We are delighted and honored to be named a Cool Vendor by Gartner, a respected authority in the enterprise technology space.

Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 14, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Cytokine, Survival, Exercise, Security (finance), Hematology, MD, TACI, Treatment, Investment, ALPN, Lupus, GN, CAML, Conference, American College, Research, Nature, BAFF, Volunteering, COVID-19, Merck & Co., Pembrolizumab, Merck, Protein engineering, Autoimmunity, Personal Data Privacy and Security Act of 2009, American College of Rheumatology, SLE, Glomerulonephritis, Randomness, NEON, AbbVie, Society, Inflammation, ASN, Patient, Pharmaceutical industry, Generic drug, Vaccine, Pharmacokinetics, Safety, IgA nephropathy, Rheumatology, Alpine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2022.
  • Collaboration revenue for the third quarter ended September 30, 2022, was $8.4 million compared to $8.5 million for the third quarter ended September 30, 2021.
  • Alpine Immune Sciences is committed to leading a new wave of immune therapeutics.
  • NEON-1, NEON-2, "Synergy," and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.

Dynam.AI Unveils Revolutionary Contextualized Machine Learning Capability as Key Part of Client Services

Retrieved on: 
Tuesday, November 15, 2022
SAN, American robotics, ROI, Anomaly, CAML, FAA, Logic, Thermography, Efficiency, Industry, Foot-pound (energy), Decision-making, Intelligence, Physics, Robotics, Artificial intelligence, CEO, AI, Data science, Machine learning, Solution, Medical device, Medical imaging

SAN DIEGO, Nov.15, 2022 /PRNewswire-PRWeb/ -- Dynam.AI, an artificial intelligence (AI) software development firm automating critical decision-making for the industrial sector, today announced a groundbreaking capability available to all clients: Context Augmented Machine Learning (CAML). CAML leverages scientific "first principles" and the laws of physics, human behavior, and macroeconomic conditions to simulate the physical world for more realistic, trustworthy analytics. This allows industrial businesses to automate manual processes, improving their critical decision making and increasing ROI with fewer resources. Dynam.AI's in-house development platform, using the patent-pending CAML method, has been proven to speed up AI model development for clients by up to 65%.

Key Points: 
  • SAN DIEGO, Nov.15, 2022 /PRNewswire-PRWeb/ -- Dynam.AI , an artificial intelligence (AI) software development firm automating critical decision-making for the industrial sector, today announced a groundbreaking capability available to all clients: Context Augmented Machine Learning (CAML) .
  • "Traditional machine learning is only able to work with the data it's given," said Dimtiry Fisher, Chief Scientific Officer at Dynam.AI.
  • To learn more about Dynam.AI's professional services, please visit: http://www.dynam.ai
    To learn more about Context-Augmented Machine Learning (CAML), please visit: https://dynam.ai/solutions/context-augmented-machine-learning/
    Dynam.AI drives smart transformations for the industrial sector.
  • Our expert data scientists tailor AI-driven solutions with next-gen machine learning capabilities that get smarter over time for each client, so they can make accurate, real-time decisions up to 65% faster with less data.

RemeGen Biosciences to Present New Data Updates in ACR 2022

Retrieved on: 
Friday, November 11, 2022
ACR, Immunoglobulin G, Multimedia, Control, Ageing, Systematic, BAFF-R, Rheumatoid arthritis, B cell, Survival, Fast track (FDA), BCMA, IgA nephropathy, PPS, National Medical Products Administration, Șaeș, III, Urinary tract infection, Immunoglobulin M, Adult, Research, Autoimmunity, American College of Rheumatology, Patient, SAN, NRDL, Lymphocyte, B-cell activating factor, CAML, ANA, Safety, SLE, American College, NMPA, Mab, Antibody, TACI, Sjögren syndrome, Population, AES, PSS, APRIL, Upper respiratory tract infection, Immunoglobulin A, Week, Pharmaceutical industry, Online shopping

This event will present Telitacicept phase III clinical trial data on Systematic lupus erythematosus (SLE) and data from the phase II clinical trial for Sjorgren's syndrome.

Key Points: 
  • This event will present Telitacicept phase III clinical trial data on Systematic lupus erythematosus (SLE) and data from the phase II clinical trial for Sjorgren's syndrome.
  • Telitacicept for Systematic Lupus Erythematosus, data from phase III trial
    This is a 52-week, randomized, double-blind, placebo-controlled, phase III clinical trial (NCT04082416).
  • RemeGen, Ltd. ("RemeGen") is a leading biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions.
  • Since its inception in 2008, RemeGen has created more than 10 novel drug molecules in various clinical development stages.

Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting

Retrieved on: 
Thursday, November 3, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Alpine, Protein engineering, Cytokine, Private Securities Litigation Reform Act, Research, BAFF, CAML, Serum, Society, HV, GN, Lupus, Adult, ALPN, SC, Securities Exchange Act of 1934, Poster, HVS Global Hospitality Services, COVID-19, Nature, Inflammation, Immunoglobulin A, Securities Act of 1933, TACI, American Society of Nephrology, U.S. Securities and Exchange Commission, Forward-looking statement, Lupus nephritis, NASDAQ, Personal Data Privacy and Security Act of 2009, GNS, Technology, Security (finance), Volunteering, Autoimmunity, Survival, MD, Treatment, Vaccine, Generic drug, Pharmacokinetics, IgA nephropathy, Safety

In addition, ALPN-303 also dose-dependently reduces serum Gd-IgA1 by up to 60%, 4 weeks after a single dose.

Key Points: 
  • In addition, ALPN-303 also dose-dependently reduces serum Gd-IgA1 by up to 60%, 4 weeks after a single dose.
  • These data support dose regimens of 80-240 mg SC every 4 weeks in future glomerulonephritis studies.
  • Alpine Immune Sciences is committed to leading a new wave of immune therapeutics.
  • Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.

Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition

Retrieved on: 
Thursday, November 3, 2022
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Alpine, Protein engineering, Cytokine, Private Securities Litigation Reform Act, Research, BAFF, CAML, Society, Lupus, Adult, ALPN, Securities Exchange Act of 1934, ASH, COVID-19, Nature, Inflammation, Securities Act of 1933, Platelet, TACI, U.S. Securities and Exchange Commission, Volunteering, Forward-looking statement, Randomized controlled trial, NASDAQ, Exposition, Technology, Security (finance), Randomness, Autoimmunity, Survival, Treatment, Pharmaceutical industry, Vaccine, Pharmacokinetics, Safety

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have a poster presentation for ALPN-303s phase 1 study (RUBY-1) at the upcoming American Society of Hematology (ASH) Annual Meeting & Exposition, December 10-13, 2022.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have a poster presentation for ALPN-303s phase 1 study (RUBY-1) at the upcoming American Society of Hematology (ASH) Annual Meeting & Exposition, December 10-13, 2022.
  • ALPN-303 is in development for multiple B cell and/or autoantibody-related diseases, such as systemic lupus erythematosus, glomerulonephritides, and autoimmune cytopenias.
  • Alpine Immune Sciences is committed to leading a new wave of immune therapeutics.
  • Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.

Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences

Retrieved on: 
Wednesday, October 26, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, LinkedIn, U.S. Securities and Exchange Commission, Protein engineering, Securities Act of 1933, CAML, Lupus, Volunteering, Cytokine, NASDAQ, Adult, Research, Twitter, Security (finance), Technology, Private Securities Litigation Reform Act, Treatment, BAFF, Nature, GN, Securities Exchange Act of 1934, ALPN, Survival, Forward-looking statement, Inflammation, TACI, Autoimmunity, COVID-19, Alpine, Vaccine, Pharmaceutical industry, Safety, Pharmacokinetics

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have poster presentations for ALPN-303 's phase 1 study (RUBY-1) at upcoming scientific conferences.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have poster presentations for ALPN-303 's phase 1 study (RUBY-1) at upcoming scientific conferences.
  • ALPN-303 is in development for multiple B cell and/or autoantibody-related diseases, such as systemic lupus erythematosus, glomerulonephritides, and autoimmune cytopenias.
  • Alpine Immune Sciences is committed to leading a new wave of immune therapeutics.
  • Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

Retrieved on: 
Monday, October 24, 2022
Biotechnology, Health, Clinical Trials, SLE, LinkedIn, U.S. Securities and Exchange Commission, Pembrolizumab, Merck, Drug Quality and Security Act, Renal cell carcinoma, Protein engineering, CAML, B-cell activating factor, BAFF, AbbVie, Cytokine, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, NEON, Merck & Co., Research, Twitter, Security (finance), Securities Act of 1933, Cancer, Technology, Private Securities Litigation Reform Act, Cardiogenic shock, Food, Company, Colectomy, Nature, Securities Exchange Act of 1934, Patient safety, Safety, CD28, ALPN, Survival, Forward-looking statement, Inflammation, Death, TACI, Autoimmunity, COVID-19, Pharmaceutical industry, Vaccine, Alpine

Patient safety remains our highest priority, said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine.

Key Points: 
  • Patient safety remains our highest priority, said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine.
  • In phase 1 studies, davoceticept has demonstrated encouraging clinical activity, especially in renal cell carcinoma, as monotherapy and in combination with pembrolizumab.
  • Alpine Immune Sciences is committed to leading a new wave of immune therapeutics.
  • NEON-1, NEON-2, "Synergy," RUBY and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.

Conning Achieves Top Score in Relevant Fixed Income Categories and Investment & Stewardship Policy in its Latest PRI Assessment Report

Retrieved on: 
Tuesday, October 4, 2022
Finance, Environmental, Social and Governance (ESG), Professional Services, Asset Management, Insurance, Perception, Solution, Principle, CHL, Responsibility, Trust, Review, Cathay, Industry, Nature, Conning, Compliance, Biophysical environment, ESG, PRI, Certification, Corporate bond, Transparency, Goal, Insurance, Social Security Government Pension Offset, Socially responsible investing, UN, United Nations Principles of Medical Ethics, Policy, Investment, Risk, Language, Task force, CAML, Principles for Responsible Investment, Board, SITE, Lithium, Risk management, Security (finance), Social

Leading global investment management firm Conning s U.S. and London-based investment operations received a five-star (out of five) rating for the four relevant categories in their latest PRI Assessment Report from the Principles for Responsible Investment (PRI).

Key Points: 
  • Leading global investment management firm Conning s U.S. and London-based investment operations received a five-star (out of five) rating for the four relevant categories in their latest PRI Assessment Report from the Principles for Responsible Investment (PRI).
  • * Their operations received a five-star rating for their Investment & Stewardship Policy as well as three fixed income categories -- including Corporates and Securitized Products in the PRI report, which offers an overarching approach to responsible and transparent investments.
  • In 2020, PRI awarded the firm an A+ score for its overarching approach to ESG Strategy and Governance.
  • A snapshot of Connings 2021 PRI Assessment Report and Transparency Report are linked here for additional information.

Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day

Retrieved on: 
Monday, September 12, 2022
Science, Other Science, Biotechnology, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Well, Adult, BAFF, Safety, Nivolumab, Nature, Renal cell carcinoma, Patient, U.S. Securities and Exchange Commission, Technology, Axitinib, NASDAQ, Research, Inflammation, Merck, Pharmacodynamics, Volunteering, RCC, CAML, Cytokine, COVID-19, Lupus, Assistant, Vanderbilt University Medical Center, Drug Quality and Security Act, Division, Company, Doctor of Philosophy, Stanford University School of Medicine, Technical, Autoimmunity, PSA, B-cell activating factor, Prostate-specific antigen, MD, Literature, Merck & Co., Review, Forward-looking statement, Neoplasm, Protein engineering, Biology, Security (finance), Pembrolizumab, Securities Exchange Act of 1934, Twitter, LinkedIn, ALPN, Private Securities Litigation Reform Act, Securities Act of 1933, Melanoma, Survival, TACI, Cancer, Pharmacokinetics, R, CD28, PD-1, Vaccine, Pharmaceutical industry, SLE, Alpine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced clinical updates from two wholly owned programs, ALPN-303 and davoceticept.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced clinical updates from two wholly owned programs, ALPN-303 and davoceticept.
  • Davoceticept, our lead Immuno-oncology program, continues to show encouraging signs of meaningful clinical activity with an acceptable safety profile.
  • Alpine Immune Sciences is committed to leading a new wave of immune therapeutics.
  • NEON-1, NEON-2, "Synergy," RUBY and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.